I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The cold and flu brand generated an impressions SOV of 4.71% and 2.9 billion impressions, primarily through CBS and its show GMA 3: What You Need to Know. The Proctor and Gamble brand invested $10.3 ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The company accomplished the feat via settlements with generics ...

AbbVie's settlement extends Rinvoq's patent protection by 12 years, enhancing market exclusivity and sales projections. Rinvoq's sales have reached $6 billion, with expectations to surpass $12 billion ...

Sept 11 (Reuters) - AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a ...

AbbVie settled litigation with companies seeking to make generic versions of Rinvoq. Assuming Rinvoq secures pediatric exclusivity, the drug won't face generic competition until 2037 at the earliest.

AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next decade. AbbVie on Thursday said it has settled ...

AbbVie has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq by more than a decade. AbbVie on Thursday said it has settled ...

AbbVie ABBV-0.68%decrease; red down pointing triangle has struck a deal with generic drugmakers aimed at extending patent protection for its blockbuster autoimmune drug Rinvoq well into the next ...

Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor FDA approved for atopic dermatitis. Upadacitinib demonstrated efficacy and ...